Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Correction: Non-invasive detection of urothelial cancer through the analysis of driver gene mutations and aneuploidy.

Springer SU, Chen CH, Rodriguez Pena MDC, Li L, Douville C, Wang Y, Cohen JD, Taheri D, Silliman N, Schaefer J, Ptak J, Dobbyn L, Papoli M, Kinde I, Afsari B, Tregnago AC, Bezerra SM, VandenBussche C, Fujita K, Ertoy D, Cunha IW, Yu L, Bivalacqua TJ, Grollman AP, Diaz LA, Karchin R, Danilova L, Huang CY, Shun CT, Turesky RJ, Yun BH, Rosenquist TA, Pu YS, Hruban RH, Tomasetti C, Papadopoulos N, Kinzler KW, Vogelstein B, Dickman KG, Netto GJ.

Elife. 2018 Nov 12;7. pii: e43237. doi: 10.7554/eLife.43237.

2.
3.

Quantitation of Aurora kinase A gene copy number in urine sediments and bladder cancer detection.

Park HS, Park WS, Bondaruk J, Tanaka N, Katayama H, Lee S, Spiess PE, Steinberg JR, Wang Z, Katz RL, Dinney C, Elias KJ, Lotan Y, Naeem RC, Baggerly K, Sen S, Grossman HB, Czerniak B.

J Natl Cancer Inst. 2008 Oct 1;100(19):1401-11. doi: 10.1093/jnci/djn304. Epub 2008 Sep 23. Erratum in: J Natl Cancer Inst. 2008 Dec 3;100(23):1740.

4.

[Detection of urothelial carcinoma of the urinary bladder by multicolor fluorescence in situ hybridization].

Zhang YG, Bi XG, Han YL, Cai Y, Xu X, Wu YP, Yang YL, Ma JH, Zhao P, Jia XM, Wang MR.

Ai Zheng. 2007 Feb;26(2):189-93. Chinese.

PMID:
17298751
5.
6.

Fluorescence in situ hybridization detects frequent chromosome 9 deletions and aneuploidy in histologically normal urothelium of bladder cancer patients.

Obermann EC, Meyer S, Hellge D, Zaak D, Filbeck T, Stoehr R, Hofstaedter F, Hartmann A, Knuechel R.

Oncol Rep. 2004 Apr;11(4):745-51.

PMID:
15010867
7.

Proteomic-based approach for biomarkers discovery in early detection of invasive urothelial carcinoma.

Li J, Abraham S, Cheng L, Witzmann FA, Koch M, Xie J, Rahman M, Mohammed SI.

Proteomics Clin Appl. 2008 Jan;2(1):78-89. doi: 10.1002/prca.200780027. Epub 2007 Dec 17.

PMID:
21136781
8.

Centrosomal abnormality is common in and a potential biomarker for bladder cancer.

Jiang F, Caraway NP, Sabichi AL, Zhang HZ, Ruitrok A, Grossman HB, Gu J, Lerner SP, Lippman S, Katz RL.

Int J Cancer. 2003 Sep 20;106(5):661-5.

9.

The Diagnosis Pattern of Mid-Trimester Fetal Chromosomal Aneuploidy in Xuzhou and the Clinical Applications.

Fang Y, Wang G, Wang C, Suo F, Gu M, Xia Y.

Cell Biochem Biophys. 2015 Nov;73(2):267-270. doi: 10.1007/s12013-015-0594-8.

PMID:
25733332
10.

Intermediate-risk urothelial carcinoma: an unresolved problem?

Pycha A, Lodde M, Comploj E, Negri G, Egarter-Vigl E, Vittadello F, Lusuardi L, Palermo S, Mian C.

Urology. 2004 Mar;63(3):472-5.

PMID:
15028440
11.

Cancer heterogeneity: converting a limitation into a source of biologic information.

Rübben A, Araujo A.

J Transl Med. 2017 Sep 8;15(1):190. doi: 10.1186/s12967-017-1290-9. Review.

12.

BubR1 alterations that reinforce mitotic surveillance act against aneuploidy and cancer.

Weaver RL, Limzerwala JF, Naylor RM, Jeganathan KB, Baker DJ, van Deursen JM.

Elife. 2016 Aug 16;5. pii: e16620. doi: 10.7554/eLife.16620.

13.

[Nested-variant urothelial carcinoma. Case report and molecular aspects].

Lindemann-Docter K, Koufou SV, Dahl E, Jakse G, Knüchel R.

Pathologe. 2008 Sep;29(5):383-6. doi: 10.1007/s00292-008-1018-y. German.

PMID:
18654782
14.

Prenatal screening for fetal aneuploidy in singleton pregnancies.

Chitayat D, Langlois S, Douglas Wilson R; SOGC GENETICS COMMITTEE; CCMG PRENATAL DIAGNOSIS COMMITTEE.

J Obstet Gynaecol Can. 2011 Jul;33(7):736-750. doi: 10.1016/S1701-2163(16)34961-1.

PMID:
21749752
15.

[Non-invasive prenatal test in the diagnosis of aneuploidy 13, 18 and 21--theoretical and practical aspects].

Stembalska A, Łaczmańska I, Lech D.

Ginekol Pol. 2011 Feb;82(2):126-32. Review. Polish.

PMID:
21574485
16.

Mutational inactivation of STAG2 causes aneuploidy in human cancer.

Solomon DA, Kim T, Diaz-Martinez LA, Fair J, Elkahloun AG, Harris BT, Toretsky JA, Rosenberg SA, Shukla N, Ladanyi M, Samuels Y, James CD, Yu H, Kim JS, Waldman T.

Science. 2011 Aug 19;333(6045):1039-43. doi: 10.1126/science.1203619.

17.

Cumulative haploinsufficiency and triplosensitivity drive aneuploidy patterns and shape the cancer genome.

Davoli T, Xu AW, Mengwasser KE, Sack LM, Yoon JC, Park PJ, Elledge SJ.

Cell. 2013 Nov 7;155(4):948-62. doi: 10.1016/j.cell.2013.10.011. Epub 2013 Oct 31.

18.

Value of multicolour fluorescence in situ hybridisation (UroVysion) in the differential diagnosis of flat urothelial lesions.

Schwarz S, Rechenmacher M, Filbeck T, Knuechel R, Blaszyk H, Hartmann A, Brockhoff G.

J Clin Pathol. 2008 Mar;61(3):272-7. Epub 2007 Aug 10.

PMID:
17693577
19.

How aneuploidy affects metabolic control and causes cancer.

Rasnick D, Duesberg PH.

Biochem J. 1999 Jun 15;340 ( Pt 3):621-30.

20.

DNA-aneuploidy as marker for neoplasia in G1-urothelial carcinomas.

Planz B, Striepecke E, Wolff JM, Effert P, Jakse G, Böcking A.

Gen Diagn Pathol. 1996 Oct;142(2):69-73.

PMID:
8950570

Supplemental Content

Support Center